Humoral and cell-mediated immune responses of humans to inactivated influenza vaccine with or without QS21 adjuvant

Vaccine

Volumn 25, Issue 17, 2007, Pages 3263-3269

  Mbawuike, I ^a   Zang, Y ^a   Couch, R B ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Antibody; Cell mediated immune responses; Granzyme B; Humans; IFN ; Immune responses; Influenza; Influenza vaccine

Indexed keywords

GAMMA INTERFERON; GRANZYME B; INACTIVATED VACCINE; INFLUENZA VACCINE; QS 21;

ADJUVANT THERAPY; ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY TEST; DRUG FATALITY; DRUG FEVER; DRUG INDUCED HEADACHE; FATIGUE; FEMALE; FREQUENCY ANALYSIS; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN EXPERIMENT; HUMORAL IMMUNITY; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS A; INFLUENZA VIRUS B; INJECTION SITE INDURATION; INJECTION SITE INFLAMMATION; INJECTION SITE PAIN; INJECTION SITE SWELLING; MALAISE; MALE; MYALGIA; NAUSEA; NORMAL HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; VOMITING;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; ANTIBODIES, VIRAL; FEMALE; HUMANS; INFLUENZA VACCINES; INTERFERON TYPE II; MALE; SAPONINS; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, INACTIVATED;

EID: 34047189362     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.01.073     Document Type: Article

References (22)

1. Stuart-Harris C.H., Schild G.C., and Oxford J.S. Immunization with influenza virus vaccines. Influenza the viruses and the disease (1985), Edward Arnold, Victoria, Australia and Baltimore, Maryland pp. 180-209
2. Keitel W.A., and Couch R.B. Inactivated influenza vaccines. In: Potter D.W. (Ed). Influenza (2002), Elsevier, Amsterdam 145-177
3. Couch R.B., Keitel W.A., and Cate T.R. Improvement of inactivated influenza virus vaccines. J Infect Dis 176 Suppl 1 (1997) S38-S44
4. Kensil C.R., Patel U., Lennick M., and Marciani D. Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex. J Immunol 146 2 (1991) 431-437
5. Kensil C.R., Newman M.J., Coughlin R.T., Soltysik S., Bedore D., Recchia J., et al. The use of stimulon adjuvant to boost vaccine response. Vaccine Res 2 4 (1993) 273-281
6. Hancock G.E., Speelman D.J., Frenchick P.J., Mineo-Kuhn M.M., Baggs R.B., and Hahn D.J. Formulation of the purified fusion protein of respiratory syncytial virus with the saponin QS-21 induces protective immune responses in Balb/c mice that are similar to those generated by experimental infection. Vaccine 13 4 (1995) 391-400
7. Wyde P.R., Guzman E., Gilbert B.E., and Couch R.B. Immunogenicity and protection in mice given inactivated influenza vaccine, MPL, QS-21 or QS-7. In: Osterhaus A.D.M.E., Cox N., and Hampson A.W. (Eds). Options for the control of influenza IV (2001), Excerpta Medica, New York 999-1005
8. Davenport F.M. Seventeen years' experience with mineral oil adjuvant influenza virus vaccines. Ann Allergy 26 (1968) 288-292
9. Dowdle W.N., Kendal A.P., and Noble G.R. Influenza viruses. In: Lennette E.H., and Schmidt N.J. (Eds). Diagnostic procedures for viral, rickettsial and chlamydial infections. 5th ed. (1979), American Public Health Association, Washington, DC 603-605
10. Frank A.L., Puck J., Hughes B.J., and Cate T.R. Microneutralization test for influenza A and B and parainfluenza 1 and 2 viruses that uses continuous cell lines and fresh serum enhancement. J Clin Microbiol 12 (1980) 426-432
11. + cytotoxic T lymphocytes. J Infect Dis 180 (1999) 1477-1486
12. Mbawuike I.N., Lange A.R., and Couch R.B. Diminished influenza A virus-specific MHC class I-restricted cytotoxic T lymphocyte activity among elderly persons. Viral Immunol 6 (1993) 55-64
13. 51Cr-release assay for monitoring cell-mediated Cytotoxicity. J Translational Med 1 (2003) 14
14. Henle W., and Henle G. Effects of adjuvants on vaccination of human beings against influenza. Proc Soc Exp Bio Med 59 (1945) 179-181
15. Meiklejohn G. Present and future of inactivated virus vaccines. Am Rev Respir Dis 88 (1963) 372-378
16. Medical Research Council. Influenza Vaccine Committee. Antibody responses and clinical reactions with saline and oil adjuvant influenza virus vaccines. Br Med J 2 (1955) 229
17. Nicholson K.G., Colegate A.E., Podda A., Stephenson I., Wood J., Ypma E., et al. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 357 (2001) 1937-1943
18. Ennis F.A., Rook A.H., Qi Y.H., Schild G.C., Riley D., et al. HLA-restricted virus-specific cytotoxic T-lymphocyte responses to live and inactivated influenza vaccines. Lancet 2 (1981) 887-891
19. Gorse G.J., and Belshe R.B. Enhancement of anti-influenza A virus. Cytotoxicity following influenza A virus vaccination in older, chronically ill adults. J Clin Microbiol 28 11 (1990) 2539-2550
20. Ennis F.A., Cruz J., Jameson J., Klein M., Burt D., and Thipphawong J. Augmentation of human influenza A virus-specific cytotoxic T lymphocyte memory by influenza vaccine and adjuvanted carriers (ISCOMS). Virology 259 (1999) 256-261
21. Powers D.C. Increased immunogenicity of inactivated influenza virus vaccine containing purified surface antigen compared with whole virus in elderly women. Clin Diagn Lab Immunol 1 (1994) 16-20
22. Lalvani A., Brookes R., Hambleton S., Britton J.W., Hill A.V., and McMichael A.J. Rapid effector function in CD8+ memory T cells. J Exp Med 186 (1997) 859-865